Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038844 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
A NA study of Lymphoma and Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT00038844 is a NA study of Lymphoma and Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 65 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00038844, a NA study of Lymphoma and Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective of the low-dose transplant regimen must produce the following effects: 1. Suppression of the patient's immune system to prevent rejection of the donor cells; 2. Control of the lymphoma. The pretransplant regimen must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the GVT effect to occur.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Campath-1 H (Alemtuzumab)
Study Locations (1)
Texas
- U.T.M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2001-06 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038844
The ClinicalTrials.gov registry entry for NCT00038844 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00038844 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00038844 about?
NCT00038844 is a clinical study titled "Safety and Efficacy of Campath in Nonmyeloablative Transplantation". Objective of the low-dose transplant regimen must produce the following effects: 1. Suppression of the patient's immune system to prevent rejection of the donor cells; 2. Control of the lymphoma. The pretransplant regimen must suppress the lymphoma sufficiently to prevent marked progression of the ...
What is the current status of trial NCT00038844?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2001-06. Estimated completion is 2010-09.
What conditions does trial NCT00038844 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00038844?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), Campath-1 H (Alemtuzumab) (DRUG).
Who is sponsoring clinical trial NCT00038844?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00038844 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.